Literature DB >> 10069717

Different phenotypic expression in relatives with fabry disease caused by a W226X mutation.

I E Knol1, M G Ausems, D Lindhout, O P van Diggelen, H Verwey, J Davies, J K Ploos van Amstel, B T Poll-The.   

Abstract

Two male relatives with Fabry disease presented striking differences in clinical symptoms and age of onset. The propositus had retarded statural growth and skeletal dysplasia while his nephew suffered mainly from aggravating acroparesthesia and celiac disease. Fabry disease is an X-linked inborn error of glycosphingolipid metabolism resulting from deficient activity of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A) enzyme. The alpha-Gal A gene is located at Xq22.1. Efforts to establish genotype-phenotype correlations have been limited because most patients have private mutations. In previous clinical studies performed in families with Fabry disease, marked differences in phenotype are described between affected relatives. This family also demonstrates the difficulty in predicting the clinical phenotype in patients and relatives with the same alpha-Gal A mutation. Furthermore, in the absence of a family history, the diagnosis may be easily missed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069717     DOI: 10.1002/(sici)1096-8628(19990219)82:5<436::aid-ajmg14>3.0.co;2-x

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

1.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

2.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

3.  The co-existence of Fabry and celiac diseases: a case report.

Authors:  Leyla Tümer; Fatih S Ezgü; Alev Hasanoğlu; Buket Dalgiç; Sevcan A Bakkaloğlu; Leyla Memiş; Ayşe Dursun
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

4.  Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.

Authors:  Kevin Mills; Ashok Vellodi; Peter Morris; Donald Cooper; Michael Morris; Elisabeth Young; Bryan Winchester
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

5.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

6.  Poikilothermia in a 38-year-old Fabry patient.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Carla E M Hollak; Wouter Wieling; Gabor E Linthorst
Journal:  Clin Auton Res       Date:  2010-12-15       Impact factor: 4.435

Review 7.  Pain management strategies for neuropathic pain in Fabry disease--a systematic review.

Authors:  Y Schuller; G E Linthorst; C E M Hollak; I N Van Schaik; M Biegstraaten
Journal:  BMC Neurol       Date:  2016-02-24       Impact factor: 2.474

8.  Detection of single nucleotide and copy number variants in the Fabry disease-associated GLA gene using nanopore sequencing.

Authors:  Albina Nowak; Omer Murik; Tzvia Mann; David A Zeevi; Gheona Altarescu
Journal:  Sci Rep       Date:  2021-11-16       Impact factor: 4.379

9.  The coincidence of IgA nephropathy and Fabry disease.

Authors:  Dita Maixnerová; Vladimír Tesař; Romana Ryšavá; Jana Reiterová; Helena Poupětová; Lenka Dvořáková; Lubor Goláň; Michaela Neprašová; Jana Kidorová; Miroslav Merta; Eva Honsová
Journal:  BMC Nephrol       Date:  2013-01-11       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.